Obesity drug submitted for approval in Japan, Novo Nordisk reports
Novo Nordisk is now aiming to have its weight loss drug Wegovy approved in Japan. In Wednesday's quarterly report, the pharmaceutical company announces that it submitted the marketing application to the Japanese authorities back in August.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN
In August, a marketing authorization application for the obesity drug Wegovy was sent off to the Japanese authorities (PMDA), Novo Nordisk reveals in its quarterly report for the third quarter.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk hopes to stabilize Wegovy supply in early 2022
For subscribers
